Use of an antibody, or antigen-binding fragment thereof, that preferentially binds to insulin-like growth factor-ii (igf-ii) with cross-reactivity to insulin-like growth factor-i (igf-i), in the manufacture of medicaments and as medicaments for the treatment of a malignant tumor in a mammal

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.